BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 11429034)

  • 1. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
    Lo A; Stratta RJ; Egidi MF; Shokouh-Amiri MH; Grewal HP; Kisilisik AT; Trofe J; Alloway RR; Gaber LW; Gaber AO
    Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ganciclovir prophylaxis for cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone.
    Lo A; Stratta RJ; Egidi MF; Kizilisik AT; Shokouh-Amiri MH; Grewal HP; Trofe J; Alloway RR; Gaber AO
    Transplant Proc; 2001; 33(1-2):1796-8. PubMed ID: 11267516
    [No Abstract]   [Full Text] [Related]  

  • 4. Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients.
    Axelrod D; Leventhal JR; Gallon LG; Parker MA; Kaufman DB
    Am J Transplant; 2005 Jun; 5(6):1423-9. PubMed ID: 15888050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression.
    Shah AP; Chen JM; Fridell JA
    Clin Transplant; 2015 Dec; 29(12):1221-9. PubMed ID: 26458498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
    Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
    Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
    Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction.
    Giral M; Nguyen JM; Daguin P; Hourmant M; Cantarovich D; Dantal J; Blancho G; Josien R; Ancelet D; Soulillou JP
    J Am Soc Nephrol; 2001 Aug; 12(8):1758-1763. PubMed ID: 11461950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus.
    Gruber SA; Garnick J; Morawski K; Sillix DH; West MS; Granger DK; El-Amm JM; Alangaden GJ; Chandrasekar P; Haririan A
    Clin Transplant; 2005 Apr; 19(2):273-8. PubMed ID: 15740567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients.
    Stratta RJ; Alloway RR; Lo A; Hodge EE;
    Transplant Proc; 2004 May; 36(4):1082-3. PubMed ID: 15194376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation.
    Kaufman DB; Leventhal JR; Gallon LG; Parker MA; Koffron AJ; Fryer JP; Abecassis MM; Stuart FP
    Transplantation; 2001 Dec; 72(12):1940-5. PubMed ID: 11773893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure of ganciclovir prophylaxis to completely eradicate CMV disease in renal transplant recipients treated with intense anti-rejection immunotherapy.
    Isenberg AL; Shen GK; Singh TP; Hahn A; Conti DJ
    Clin Transplant; 2000 Jun; 14(3):193-8. PubMed ID: 10831076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ; Alloway RR; Hodge E; Lo A;
    Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
    Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
    Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
    Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
    Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
    Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases.
    Kaufman DB; Leventhal JR; Stuart J; Abecassis MM; Fryer JP; Stuart FP
    Transplantation; 1999 Feb; 67(4):586-93. PubMed ID: 10071032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.